Finding ways to overcome resistance to radiation therapy in brain tumors.
Official title: Project 2: Overcoming GBM RT-resistance
Funded at University of Michigan at Ann Arbor · NIH-10917028 · Data updated 2026-11-12
This study is looking at how certain healthy cells around glioblastoma tumors might make the tumors tougher against radiation, and it aims to test a new treatment that combines a safe drug with regular radiation and chemotherapy to help improve outcomes for patients with this challenging brain cancer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project start | August 14, 2023 |
| Project end | July 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $230,479 |
| NIH project number | 5P50CA269022-02 |
| Project ID | NIH-10917028 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with glioblastoma who are undergoing standard treatment involving radiation and chemotherapy.
✕Less likely to help
Patients with other types of brain tumors or those who are not receiving radiation therapy may not benefit from this research.
What this research studies
This research focuses on glioblastoma (GBM), a highly aggressive brain tumor that often does not respond well to radiation therapy. The team aims to understand how non-cancerous cells in the tumor environment contribute to the tumor's resistance to radiation. By studying the metabolic processes involved, they plan to test a combination of an FDA-approved drug with standard radiation and chemotherapy in patients. This approach is designed to improve treatment outcomes for those affected by GBM.
Why it matters
Potential benefit: If successful, this research could lead to improved survival rates and treatment responses for patients with glioblastoma.
How similar studies have gone: Previous research has shown promise in targeting metabolic pathways in cancer treatment, suggesting potential for success in this approach.
Where this research is happening
-
University of Michigan at Ann Arbor
Ann Arbor, United States Active
Researchers
- Principal investigator: Wahl, Daniel R — University of Michigan at Ann Arbor
- Study coordinator: Wahl, Daniel R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.